drugset / Trial / NCT01990326

Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat

NCT01990326 ↗

Phase 2 Suspended 27 enrolled Topokine Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the effects of XAF5 Gel (applied to skin each night for 6 weeks) on excess submental fat, also known as double chin. The study will also assess the safety and tolerability of XAF5 Gel.

Timeline

Start
2013-11
Primary completion
2014-06
Completion
—

Outcome

Outcome not reported

Stopped (Business): “Feasibility cohorts competed. Efficacy cohort not initiated for business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject XAF5 Unknown — Topical

Indications

No indication recorded.